{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:28:02Z","timestamp":1790119682715,"version":"4.0.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Bislang sind nur wenige Medikamente zur pharmakologischen R\u00fcckfallprophylaxe der Alkoholabh\u00e4ngigkeit zugelassen. Neben dem in Deutschland nicht mehr vertriebenen Disulfiram sind es die Opioidantagonisten Naltrexon und Nalmefen sowie das vermutlich \u00fcber glutamaterge Neurone wirkende Acamprosat. Baclofen und \u03b3\u2011Hydroxybutyrat (GHB) sind in einzelnen L\u00e4ndern zugelassen. Wirkstoffe wie z.\u202fB. Vareniclin, Gabapentin und Topiramat k\u00f6nnen f\u00fcr die R\u00fcckfallprophylaxe der Alkoholabh\u00e4ngigkeit von Interesse sein, jedoch ist bislang keine Zulassung erfolgt. Vor dem Hintergrund der zur Revision anstehenden S3-Leitlinie zur Diagnose und Behandlung alkoholbezogener St\u00f6rungen wird der heutige Kenntnisstand zur Pharmakotherapie der Alkoholabh\u00e4ngigkeit dargestellt.<\/jats:p>","DOI":"10.1007\/s00115-020-00954-5","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T12:03:41Z","timestamp":1595333021000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmakotherapie der Alkoholentw\u00f6hnung: Update und neue Entwicklungen","Pharmacotherapy of alcohol withdrawal: update and new developments"],"prefix":"10.1007","volume":"92","author":[{"given":"Michael","family":"Soyka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"R\u00f6sner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"954_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/alcalc\/37.5.504","volume":"37","author":"G Addolorato","year":"2002","unstructured":"Addolorato\u00a0G, Caputo\u00a0F, Capristo\u00a0E et al (2002) Baclofen efficacy in reducing alcohol craving and intake: a\u00a0preliminary double-blind study randomized controlled study. Alcohol Alcohol 37:123\u2013135","journal-title":"Alcohol Alcohol"},{"key":"954_CR2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato\u00a0G, Leggio\u00a0L, Ferulli\u00a0A et al (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 370:1915\u20131922","journal-title":"Lancet"},{"key":"954_CR3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","volume":"46","author":"G Addolorato","year":"2011","unstructured":"Addolorato\u00a0G, Leggio\u00a0L, Ferrulliu\u00a0A et al (2011) Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a\u00a0randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 46:312\u2013317","journal-title":"Alcohol Alcohol"},{"issue":"4","key":"954_CR4","first-page":"CD008581","volume":"4","author":"R Agabio","year":"2018","unstructured":"Agabio\u00a0R, Trogu\u00a0E, Pani\u00a0PP (2018) Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev 4(4):CD8581","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"954_CR5","doi-asserted-by":"crossref","first-page":"19r02465","DOI":"10.4088\/PCC.19r02465","volume":"21","author":"S Ahmed","year":"2019","unstructured":"Ahmed\u00a0S, Stanciu\u00a0CN, Kotapati\u00a0PV (2019) Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review. Prim Care Companion CNS Disord 21(4):19r02465","journal-title":"Prim Care Companion CNS Disord"},{"issue":"10","key":"954_CR6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/01.ALC.0000091223.72517.13","volume":"27","author":"JP Allen","year":"2003","unstructured":"Allen\u00a0JP (2003) Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a\u00a0conference sponsored by the national institute on alcohol abuse and alcoholism. Alcohol Clin Exp Res 27(10):1657\u20131660","journal-title":"Alcohol Clin Exp Res"},{"key":"954_CR7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","volume":"40","author":"O Ameisen","year":"2005","unstructured":"Ameisen\u00a0O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a\u00a0self-case report of a\u00a0physician. Alcohol Alcohol 40:147\u2013150","journal-title":"Alcohol Alcohol"},{"key":"954_CR8","volume-title":"Diagnostische und Statistische Manual Psychischer St\u00f6rungen","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostische und Statistische Manual Psychischer St\u00f6rungen, 5.\u00a0Aufl. American Psychiatric Publishing, Arlington, VA","edition":"5"},{"issue":"17","key":"954_CR9","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton\u00a0RF, O\u2019Malley\u00a0SS, Ciraulo\u00a0DA et\u00a0al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a\u00a0randomized controlled trial. JAMA 295(17):2003\u20132017","journal-title":"JAMA"},{"issue":"11","key":"954_CR10","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2217\/pgs.15.72","volume":"16","author":"IE Bauer","year":"2015","unstructured":"Bauer\u00a0IE, Graham\u00a0DP, Soares\u00a0JC et al (2015) Serotonergic gene variation in substance use pharma-cotherapy: a\u00a0systematic review. Pharmacogenomics 16(11):1307\u20131314","journal-title":"Pharmacogenomics"},{"issue":"12","key":"954_CR11","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","volume":"26","author":"EM Beraha","year":"2016","unstructured":"Beraha\u00a0EM, Salemink\u00a0E, Goudriaan\u00a0AE et al (2016) Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol 26(12):1950\u20131959","journal-title":"Eur Neuropsychopharmacol"},{"key":"954_CR12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett\u00a0JC, Del Re\u00a0AC, Maisel\u00a0NC et al (2014) A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 38:1481\u20131488","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"954_CR13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","volume":"17","author":"M Bolton","year":"2019","unstructured":"Bolton\u00a0M, Hodkinson\u00a0A, Boda\u00a0S et al (2019) Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a\u00a0systematic review and meta-analysis. BMC Med 17(1):10","journal-title":"BMC Med"},{"issue":"4","key":"954_CR14","first-page":"269","volume":"47","author":"R Brambilla","year":"2012","unstructured":"Brambilla\u00a0R, Vigna-Taglianti\u00a0F, Avanzi\u00a0G et al (2012) Il gamma-idrossibutirrato (GHB) nel trattamento a\u00a0medio\/lungo termine della dipendenza da alcol: una revisione sistematica [gamma-hydroxybutyrate (GHB) for mid\/long term treatment of alcohol dependence: a\u00a0systematic review. Riv Psichiatr 47(4):269\u2013280","journal-title":"Riv Psichiatr"},{"issue":"3","key":"954_CR15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","volume":"138","author":"T Bschor","year":"2018","unstructured":"Bschor\u00a0T, Henssler\u00a0J, M\u00fcller\u00a0M et al (2018) Baclofen for alcohol use disorder\u2014a systematic meta-analysis. Acta Psychiatr Scand 138(3):232\u2013242","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"954_CR16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000494692","volume":"24","author":"P Castera","year":"2018","unstructured":"Castera\u00a0P, Stewart\u00a0E, Gro\u00dfkopf\u00a0J et al (2018) Nalmefene, given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care. Eur Addict Res 24(6):293\u2013303","journal-title":"Eur Addict Res"},{"key":"954_CR17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pds.4635","volume":"27","author":"C Chaignot","year":"2018","unstructured":"Chaignot\u00a0C, Zureik\u00a0M, Rey\u00a0G et\u00a0al (2018) Risk of hospitalization and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a\u00a0cohort study of 165334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf 27:1239\u20131248","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"954_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2019.02.003","volume":"149","author":"NA Crowley","year":"2019","unstructured":"Crowley\u00a0NA, Magee\u00a0SN, Feng\u00a0M et al (2019) Ketamine normalizes binge drinking-induced defects in glutamatergic synaptic transmission and ethanol drinking behavior in female but not male rats. Neuropharmacology 149:35\u201344","journal-title":"Neuropharmacology"},{"issue":"1","key":"954_CR19","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1038\/s41467-019-13162-w","volume":"10","author":"RK Das","year":"2019","unstructured":"Das\u00a0RK, Gale\u00a0G, Walsh\u00a0K et\u00a0al (2019) Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun 10(1):5187","journal-title":"Nat Commun"},{"key":"954_CR20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fpsyt.2018.00506","volume":"9","author":"R de Beaurepaire","year":"2018","unstructured":"de Beaurepaire\u00a0R (2018) A review of the potential mechanisms of action of baclofen in alcohol use disorder. Front Psychiatry 9:506","journal-title":"Front Psychiatry"},{"key":"954_CR21","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/acer.12854","volume":"39","author":"A de Bejczy","year":"2015","unstructured":"de Bejczy\u00a0A, Lof\u00a0E, Walther\u00a0L et al (2015) Varenicline for treatment of alcohol dependence: a\u00a0randomized, placebo-controlled trial. Alcohol Clin Exp Res 39:2189\u20132199","journal-title":"Alcohol Clin Exp Res"},{"key":"954_CR22","volume-title":"Internationale Klassifikation psychischer St\u00f6rungen","author":"H Dilling","year":"2015","unstructured":"Dilling\u00a0H, Mombour\u00a0W, Schmidt\u00a0M (2015) Internationale Klassifikation psychischer St\u00f6rungen, 10.\u00a0Aufl. Huber, Bern (ICD-10 Kapitel V (F))","edition":"10"},{"issue":"6","key":"954_CR23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","volume":"110","author":"K Donoghue","year":"2015","unstructured":"Donoghue\u00a0K, Elzerbi\u00a0C, Saunders\u00a0R (2015) The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a\u00a0meta-analysis. Addiction 110(6):920\u2013930","journal-title":"Addiction"},{"key":"954_CR24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1360-0443.1988.tb01584.x","volume":"83","author":"G Edwards","year":"1988","unstructured":"Edwards\u00a0G, Brown\u00a0D, Oppenheimer\u00a0E et\u00a0al (1988) Long term outcome for patients. With drinking problems: the search for predictors. Br J Addict 83:917\u2013927","journal-title":"Br J Addict"},{"key":"954_CR25","volume-title":"Guideline on the development of medicinal products for the treatment of alcohol dependence","author":"European Medicines Agency","year":"2010","unstructured":"European Medicines Agency (2010) Guideline on the development of medicinal products for the treatment of alcohol dependence. European Medicines Agency, London"},{"issue":"4","key":"954_CR26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","volume":"76","author":"DE Falk","year":"2019","unstructured":"Falk\u00a0DE, O\u2019Malley\u00a0SS, Witkiewitz\u00a0K et\u00a0al (2019) Alcohol clinical trials initiative (ACTIVE) workgroup. Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. JAMA Psychiatry 76(4):374\u2013381","journal-title":"JAMA Psychiatry"},{"key":"954_CR27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.physbeh.2019.02.008","volume":"204","author":"M Farokhnia","year":"2019","unstructured":"Farokhnia\u00a0M, Faulkner\u00a0ML, Piacentino\u00a0D et\u00a0al (2019) From a\u00a0gut hormone to a\u00a0potential therapeutic target for alcohol use disorder. Physiol Behav 204:49\u201357","journal-title":"Physiol. Behav."},{"key":"954_CR28","first-page":"14477","volume":"111","author":"N Fitzgerald","year":"2016","unstructured":"Fitzgerald\u00a0N, Angus\u00a0K, Elders\u00a0A et\u00a0al (2016) Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction 111:14477\u201311487","journal-title":"Addiction"},{"key":"954_CR29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40263-016-0390-z","volume":"30","author":"R Freynhagen","year":"2016","unstructured":"Freynhagen\u00a0R, Backonja\u00a0M, Schug\u00a0S et\u00a0al (2016) Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs 30:1191\u20131200","journal-title":"CNS Drugs"},{"issue":"11","key":"954_CR30","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"RK Fuller","year":"1986","unstructured":"Fuller\u00a0RK, Branchey\u00a0L, Brightwell\u00a0DR et\u00a0al (1986) Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA 256(11):1449\u20131455","journal-title":"JAMA"},{"key":"954_CR31","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt\u00a0JC, Kampov-Polevoy\u00a0AB, Gallop\u00a0P (2010) Efficacy and safety of baclofen for alcohol dependence: a\u00a0randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34:1849\u20131857","journal-title":"Alcohol Clin Exp Res"},{"issue":"13","key":"954_CR32","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","volume":"293","author":"JC Garbutt","year":"2005","unstructured":"Garbutt\u00a0JC, Kranzler\u00a0HR, O\u2019Malley\u00a0SS, Vivitrex Study Group et al (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a\u00a0randomized controlled trial. JAMA 293(13):1617\u20131625","journal-title":"JAMA"},{"key":"954_CR33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/apt.13965","volume":"45","author":"ET Goh","year":"2017","unstructured":"Goh\u00a0ET, Morgan\u00a0MY (2017) Review article: pharmacotherapy for alcohol dependence\u2014the why, the what and the wherefore. Aliment Pharmacol Ther 45:865\u2013882","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"954_CR34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant\u00a0BF, Goldstein\u00a0RB, Saha\u00a0TD et al (2015) Epidemiology of DSM\u20115 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry 72(8):757\u2013766","journal-title":"JAMA Psychiatry"},{"key":"954_CR35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","volume":"23","author":"A Gual","year":"2013","unstructured":"Gual\u00a0A, He\u00a0Y, Torup\u00a0L et al (2013) A randomized, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 23:1432\u20131442","journal-title":"Eur Neuropsychopharmacol"},{"key":"954_CR36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00213-018-4843-6","volume":"235","author":"CL Haass-Koffler","year":"2018","unstructured":"Haass-Koffler\u00a0CL, Swift\u00a0RM (2018) Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology 235:1625\u20131634","journal-title":"Psychopharmacology"},{"key":"954_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neubiorev.2018.09.010","volume":"106","author":"AC Hansson","year":"2019","unstructured":"Hansson\u00a0AC, Gr\u00fcnder\u00a0G, Hirth\u00a0N et\u00a0al (2019) Dopamine and opioid systems adaptation in alcoholism revisited: convergent evidence from positron emission tomography and postmortem studies. Neurosci Biobehav Rev 106:141\u2013164","journal-title":"Neurosci Biobehav Rev"},{"key":"954_CR38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/17425255.2019.1628218","volume":"15","author":"EE Hartwell","year":"2019","unstructured":"Hartwell\u00a0EE, Kranzler\u00a0KR (2019) Pharmacogenetics of alcohol use disorder treatments: an update. Expert Opin Drug Metab Toxicol 15:553\u2013564","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"954_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/add.14975","author":"EE Hartwell","year":"2020","unstructured":"Hartwell\u00a0EE, Feinn\u00a0R, Morris\u00a0PE (2020) Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the Mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. https:\/\/doi.org\/10.1111\/add.14975","journal-title":"Addiction"},{"key":"954_CR40","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/acer.13884","volume":"42","author":"DS Hasin","year":"2018","unstructured":"Hasin\u00a0DS, Wall\u00a0M, Witkiewitz\u00a0K et al (2018) Change in non-abstinent, WHO drinking risk levels and alcohol dependence, A 3 year follow-up results in the US general polulation. Alcohol Clin Exp Res 42:2256\u20132265","journal-title":"Alcohol Clin Exp Res"},{"key":"954_CR41","volume-title":"Bacloville: clinical efficacy study of high dose baclofen in reducing alcohol consumption in high risk drinkers","author":"P Jaury","year":"2016","unstructured":"Jaury\u00a0P (2016) Bacloville: clinical efficacy study of high dose baclofen in reducing alcohol consumption in high risk drinkers. Berlin ISBRA Congress, Berlin"},{"key":"954_CR42","first-page":"265275","volume":"168","author":"BA Johnson","year":"2011","unstructured":"Johnson\u00a0BA, Ait-Daoud\u00a0C, Seneviratne\u00a0J et al (2011) Pharmacogenetic approach at the serotonin transporter gene as a\u00a0method of reducing the severity of alcohol drinking. Am J Psychiatry 168:265275","journal-title":"Am J Psychiatry"},{"issue":"18","key":"954_CR43","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas\u00a0DE, Amick\u00a0HR, Feltner\u00a0C et al (2014) Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a\u00a0systematic review and meta-analysis. JAMA 311(18):1889\u20131900","journal-title":"JAMA"},{"key":"954_CR44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","volume":"34","author":"GM Keating","year":"2014","unstructured":"Keating\u00a0GM (2014) Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig 34:63\u201380","journal-title":"Clin Drug Investig"},{"key":"954_CR45","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/acer.12410","volume":"38","author":"GA Kenna","year":"2014","unstructured":"Kenna\u00a0GA, Zywiak\u00a0WH, Swift\u00a0RM et al (2014) Ondansetron reduces naturalistic drinking in non-treatment-seeking alcohol-dependent individuals with the LL 5\u2019-HTTLPR genotype: a\u00a0laboratory study. Alcohol Clin Exp Res 38:1567\u20131574","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"954_CR46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"F Kiefer","year":"2003","unstructured":"Kiefer\u00a0F, Jahn\u00a0H, Tarnaske\u00a0T et al (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a\u00a0double-blind, placebo-controlled study. Arch Gen Psychiatry 60(1):92\u201399","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"954_CR47","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.4088\/JCP.12r08178","volume":"74","author":"T Kishi","year":"2013","unstructured":"Kishi\u00a0T, Devy\u00a0S, Chekuri\u00a0R et al (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J\u00a0Clin Psychiatry 74(7):e642\u201354","journal-title":"J Clin Psychiatry"},{"key":"954_CR48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugalcdep.2018.06.015","volume":"190","author":"EM Klemperer","year":"2018","unstructured":"Klemperer\u00a0EM, Hughes\u00a0JR, Naud\u00a0S (2018) Study characteristics influence the efficacy of substance abuse treatments: a meta-analysis of medications for alcohol use disorder. Drug Alcohol Depend 190:229\u2013234","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"954_CR49","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1530-0277.2011.01519.x","volume":"35","author":"H Krampe","year":"2011","unstructured":"Krampe\u00a0H, Spies\u00a0CD, Ehrenreich\u00a0H (2011) Supervised disulfiram in the treatment of alcohol use disorder: a\u00a0commentary. Alcohol Clin Exp Res 35(10):1732\u20131736","journal-title":"Alcohol Clin Exp Res"},{"key":"954_CR50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler\u00a0HR, Covault\u00a0J, Feinn\u00a0R et\u00a0al (2014a) Topiramate treatment for heavy drinkers: moderation by a\u00a0GRIK1 polymorphism. Am J Psychiatry 171:445\u2013452","journal-title":"Am J Psychiatry"},{"key":"954_CR51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1017\/S1461145714000510","volume":"17","author":"HR Kranzler","year":"2014","unstructured":"Kranzler\u00a0HR, Armeli\u00a0S, Feinn\u00a0R et\u00a0al (2014b) GRIK1 genotype moderates topiramate\u2019s effects on daily drinking level, expectations of alcohols positive effects and desire to drink. Int J Neuropsychopharmacol 17:1549\u20131556","journal-title":"Int J Neuropsychopharmacol"},{"key":"954_CR52","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","volume":"114","author":"HR Kranzler","year":"2019","unstructured":"Kranzler\u00a0HR, Feinn\u00a0R, Morris\u00a0P et al (2019) A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction 114:1547\u20131555","journal-title":"Addiction"},{"key":"954_CR53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","volume":"320","author":"HR Kranzler","year":"2018","unstructured":"Kranzler\u00a0HR, Soyka\u00a0M (2018) Diagnosis and pharmacotherapy of alcohol use disorder. A review. JAMA 320:815\u2013826","journal-title":"JAMA"},{"key":"954_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_295","author":"L Leggio","year":"2019","unstructured":"Leggio\u00a0L, Falk\u00a0DE, Ryan\u00a0ML (2019) Medication development for alcohol use disorder: a focus on clinical studies. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/164_2019_295","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"954_CR55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","volume":"200","author":"S Leucht","year":"2012","unstructured":"Leucht\u00a0S, Hierl\u00a0S, Kissling\u00a0W (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200(2):97\u2013106","journal-title":"Br J Psychiatry"},{"key":"954_CR56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","volume":"7","author":"RZ Litten","year":"2013","unstructured":"Litten\u00a0RZ, Ryan\u00a0ML, Fertig\u00a0JR et al (2013) A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J\u00a0Addict Med 7:277\u2013286","journal-title":"J Addict Med"},{"issue":"2","key":"954_CR57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","volume":"108","author":"NC Maisel","year":"2013","unstructured":"Maisel\u00a0NC, Blodgett\u00a0JC, Wilbourne\u00a0PL et al (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disoorders: when are these medications most helpful? Addiction 108(2):275\u2013293","journal-title":"Addiction"},{"key":"954_CR58","doi-asserted-by":"crossref","first-page":"10931105","DOI":"10.1037\/ccp0000447","volume":"87","author":"M Magill","year":"2019","unstructured":"Magill\u00a0M, Ray\u00a0L, Kiluk\u00a0B et al (2019) A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition. J\u00a0Consult Clin Psychol 87:10931105","journal-title":"J Consult Clin Psychol"},{"key":"954_CR59","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-47086-2","volume-title":"S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen","author":"K Mann","year":"2016","unstructured":"Mann\u00a0K, Hoch\u00a0E, Batra\u00a0A (2016) S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen. Springer, Heidelberg, Berlin"},{"key":"954_CR60","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","volume":"73","author":"K Mann","year":"2013","unstructured":"Mann\u00a0K, Bladstr\u00f6m\u00a0A, Torup\u00a0L et al (2013) Extending the treatment options in alcohol dependence: a\u00a0randomized controlled study of as-needed nalmefene. Biol Psychiatry 73:706\u2013713","journal-title":"Biol Psychiatry"},{"key":"954_CR61","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1360-0443.1994.tb03308.x","volume":"89","author":"EJ Marshall","year":"1994","unstructured":"Marshall\u00a0EJ, Edwards\u00a0G, Taylor\u00a0C (1994) Mortality in men with drinking problems: a\u00a020-year follow-up. Addiction 89:1293\u20131298","journal-title":"Addiction"},{"key":"954_CR62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","volume":"27","author":"BJ Mason","year":"2018","unstructured":"Mason\u00a0BJ, Quello\u00a0S, Shadan\u00a0F (2018) Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs 27:113\u2013124","journal-title":"Expert Opin Investig Drugs"},{"issue":"17","key":"954_CR63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.15288\/jsads.2014.s17.68","volume":"75","author":"BS McCrady","year":"2014","unstructured":"McCrady\u00a0BS, Owens\u00a0MD, Borders\u00a0AZ (2014) Psychosocial approaches to alcohol use disorders since 1940: a\u00a0review. J\u00a0Stud Alcohol Drugs Suppl 75(17):68\u201378","journal-title":"J Stud Alcohol Drugs Suppl"},{"key":"954_CR64","first-page":"867","volume":"27","author":"WR Miller","year":"2002","unstructured":"Miller\u00a0WR, Wilbourne\u00a0PL (2002) Mesa grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 27:867\u2013886","journal-title":"Addiction"},{"key":"954_CR65","first-page":"CD012557","volume":"11","author":"S Minozzi","year":"2018","unstructured":"Minozzi\u00a0S, Saulle\u00a0R, R\u00f6sner\u00a0S (2018) Baclofen for alcohol use disorder. Cochrane Database Syst Rev 11:CD12557","journal-title":"Cochrane Database Syst Rev"},{"key":"954_CR66","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/pcn.12914","volume":"73","author":"H Miyata","year":"2019","unstructured":"Miyata\u00a0H, Takahashi\u00a0M, Murai\u00a0Y et al (2019) Nalmefene in alcohol-dependent patients with a\u00a0high drinking risk: randomized controlled trial. Psychiatry Clin Neurosci 73:697\u2013706","journal-title":"Psychiatry Clin Neurosci"},{"key":"954_CR67","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","volume":"49","author":"KC Morley","year":"2014","unstructured":"Morley\u00a0KC, Baillie\u00a0A, Leung\u00a0S et\u00a0al (2014) Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol 49:654\u2013660","journal-title":"Alcohol Alcohol"},{"issue":"12","key":"954_CR68","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/add.14373","volume":"113","author":"KC Morley","year":"2018","unstructured":"Morley\u00a0KC, Luquin\u00a0N, Baillie\u00a0A (2018) Moderation of baclofen response by a\u00a0GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction 113(12):2205\u20132213","journal-title":"Addiction"},{"key":"954_CR69","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","volume":"25","author":"CA M\u00fcller","year":"2015","unstructured":"M\u00fcller\u00a0CA, Geisel\u00a0O, Pelz\u00a0P et al (2015) High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a\u00a0randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25:1167\u20131177","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"954_CR70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0042-103592","volume":"49","author":"J Mutschler","year":"2016","unstructured":"Mutschler\u00a0J, Grosshans\u00a0M, Soyka\u00a0M (2016) Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry 49(4):137\u2013141","journal-title":"Pharmacopsychiatry"},{"key":"954_CR71","volume-title":"Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence","author":"National Institute for Health and Care Excellence","year":"2011","unstructured":"National Institute for Health and Care Excellence (2011) Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. National Institute for Health and Care Excellence, London"},{"key":"954_CR72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12916-016-0664-9","volume":"14","author":"F Naudet","year":"2016","unstructured":"Naudet\u00a0F, Palpaceur\u00a0V, Boussageon\u00a0R (2016) Evaluation in alcohol use disorders\u2014insights from the nalmefene experience. BMC Med 14:119\u2013127","journal-title":"BMC Med"},{"issue":"11","key":"954_CR73","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O\u2019Malley","year":"1992","unstructured":"O\u2019Malley\u00a0SS, Jaffe\u00a0AJ, Chang\u00a0G (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49(11):881\u2013887","journal-title":"Arch Gen Psychiatry"},{"key":"954_CR74","doi-asserted-by":"crossref","first-page":"107631","DOI":"10.1016\/j.drugalcdep.2019.107631","volume":"205","author":"A Oon-Arom","year":"2019","unstructured":"Oon-Arom\u00a0A, Likhitsathian\u00a0S, Srisuraparont\u00a0M (2019) Efficacy and acceptability of varenicline for alcoholism: a systematic review and meta-analysis of randomized-controlled trials. Drug Alcohol Depend 205:107631","journal-title":"Drug Alcohol Depend"},{"key":"954_CR75","doi-asserted-by":"crossref","first-page":"e1001924","DOI":"10.1371\/journal.pmed.1001924","volume":"12","author":"C Palpacuer","year":"2015","unstructured":"Palpacuer\u00a0C, Laviolle\u00a0B, Boussageon\u00a0R et al (2015) Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a\u00a0systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med 12:e1001924","journal-title":"PLoS Med"},{"issue":"2","key":"954_CR76","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","volume":"113","author":"C Palpacuer","year":"2018","unstructured":"Palpacuer\u00a0C, Duprez\u00a0R, Huneau\u00a0A et al (2018) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a\u00a0systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113(2):220\u2013237","journal-title":"Addiction"},{"key":"954_CR77","first-page":"Cd008544","volume":"2","author":"PP Pani","year":"2014","unstructured":"Pani\u00a0PP, Trogu\u00a0E, Pacini\u00a0M et\u00a0al (2014) Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev 2:Cd8544","journal-title":"Cochrane Database Syst Rev"},{"key":"954_CR78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","volume":"52","author":"AM Ponizovsky","year":"2015","unstructured":"Ponizovsky\u00a0AM, Rosca\u00a0P, Aronovich\u00a0E et al (2015) Baclofen as add-on to standrard psychosocial treatment for alcohol dependence: a\u00a0randomized, double-blind, placebo controlled trial with 1 year follow-up. J\u00a0Subst Abuse Treat 52:24\u201330","journal-title":"J Subst Abuse Treat"},{"key":"954_CR79","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1389201018666170224105025","volume":"18","author":"G Ragia","year":"2017","unstructured":"Ragia\u00a0G, Manopoulos\u00a0VG (2017) Personalized medicine of alcohol addiction: pharmacogenomics and beyond. Curr Pharm Biotechnol 18:221\u2013230","journal-title":"Curr Pharm Biotechnol"},{"key":"954_CR80","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/adb.12747","volume":"24","author":"LA Ray","year":"2019","unstructured":"Ray\u00a0LA, Green\u00a0RJ, Roche\u00a0DJO et al (2019) Naltrexone effects on subjective responses to alcohol in the human laboratory: a systematic review and meta-analysis. Addict Biol 24:1138\u20131152","journal-title":"Addict Biol"},{"issue":"4","key":"954_CR81","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/acer.12331","volume":"38","author":"J Rehm","year":"2014","unstructured":"Rehm\u00a0J, Dawson\u00a0D, Frick\u00a0U et\u00a0al (2014) Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res 38(4):1068\u20131077","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"954_CR82","doi-asserted-by":"crossref","first-page":"439446","DOI":"10.1093\/alcalc\/agx030","volume":"52","author":"M Reynaud","year":"2017","unstructured":"Reynaud\u00a0M, Aubin\u00a0H\u2011J, Trinquet\u00a0F et al (2017) A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients\u2014the ALPADIR study. Alcohol Alcohol 52(4):439446","journal-title":"Alcohol Alcohol"},{"key":"954_CR83","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/pgs.14.143","volume":"16","author":"DJO Roche","year":"2015","unstructured":"Roche\u00a0DJO, Ray\u00a0LA (2015) Subjective response as a\u00a0consideration in the pharmacogenetics of alcoholism treatment. Pharmacogenomics 16:721\u2013726","journal-title":"Pharmacogenomics"},{"key":"954_CR84","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","volume":"25","author":"B Rolland","year":"2015","unstructured":"Rolland\u00a0B, Labreuche\u00a0J, Duhamel\u00a0A et\u00a0al (2015) Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 25:1631\u20131636","journal-title":"Eur Neuropsychopharmacol"},{"key":"954_CR85","first-page":"CD004332","volume":"9","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner\u00a0S, Hackl-Herrwerth\u00a0A, Leucht\u00a0S et al (2010a) Acamprosate for alcohol dependence. Cochrane Database Syst Rev 9:CD4332","journal-title":"Cochrane Database Syst Rev"},{"key":"954_CR86","first-page":"CD001867","volume":"12","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner\u00a0S, Hackl-Herrwerth\u00a0A, Leucht\u00a0S et al (2010b) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12:CD1867","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"954_CR87","first-page":"47","volume":"16","author":"S R\u00f6sner","year":"2014","unstructured":"R\u00f6sner\u00a0S, Grosshans\u00a0M, Mutschler\u00a0JH (2014) Disulfiram: Aktuelle Befunde und Wirkmechanismen. Suchtmedizin 16(2):47\u201352","journal-title":"Suchtmedizin"},{"key":"954_CR88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40263-019-00644-0","volume":"33","author":"S R\u00f6sner","year":"2019","unstructured":"R\u00f6sner\u00a0S, Soyka\u00a0M (2019) Outcome assessment in trials of pharmacological treatments for alcohol use disorders. CNS Drugs 33:649\u2013657","journal-title":"CNS Drugs"},{"issue":"12","key":"954_CR89","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1176\/appi.ajp.2018.17080913","volume":"175","author":"TL Simpson","year":"2018","unstructured":"Simpson\u00a0TL, Saxon\u00a0AJ, Stappenbeck\u00a0C et al (2018) Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry 175(12):1216\u20131224","journal-title":"Am J Psychiatry"},{"key":"954_CR90","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40264-016-0416-y","volume":"39","author":"JM Sinclair","year":"2016","unstructured":"Sinclair\u00a0JM, Chambers\u00a0SE, Shiles\u00a0CJ et\u00a0al (2016) Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf 39:627\u2013645","journal-title":"Drug Saf"},{"issue":"3","key":"954_CR91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.drugalcdep.2010.06.011","volume":"112","author":"MD Skinner","year":"2010","unstructured":"Skinner\u00a0MD, Coudert\u00a0M, Berlin\u00a0I et al (2010) Effect of the threat of a\u00a0disulfiram-ethanol reaction on cue reactivity in alcoholics. Drug Alcohol Depend 112(3):239\u2013246","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"954_CR92","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","volume":"9","author":"MD Skinner","year":"2014","unstructured":"Skinner\u00a0MD, Lahmek\u00a0P, Pham\u00a0H et al (2014) Disulfiram efficacy in the treatment of alcohol dependence: a\u00a0meta-analysis. PLoS One 9(2):e87366","journal-title":"PLoS One"},{"issue":"12","key":"954_CR93","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","volume":"18","author":"M Soyka","year":"2017","unstructured":"Soyka\u00a0M, M\u00fcller\u00a0CA (2017) Pharmacotherapy of alcoholism\u2014an update on approved and off-label medications. Expert Opin Pharmacother 18(12):1187\u20131199","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"954_CR94","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2016.1146689","volume":"7","author":"M Soyka","year":"2016","unstructured":"Soyka\u00a0M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 7(4):619\u2013626","journal-title":"Expert Opin Pharmacother"},{"key":"954_CR95","volume-title":"Suchtmedizin","year":"2019","unstructured":"Soyka\u00a0M, Batra\u00a0A, Heinz\u00a0A et\u00a0al (Hrsg) (2019) Suchtmedizin. Elsevier, M\u00fcnchen"},{"issue":"4","key":"954_CR96","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","volume":"39","author":"R Spanagel","year":"2014","unstructured":"Spanagel\u00a0R, Vengeliene\u00a0V, Jandeleit\u00a0B et al (2014) Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 39(4):783\u2013791","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"954_CR97","first-page":"285","volume":"5","author":"C Stanciu","year":"2017","unstructured":"Stanciu\u00a0C, Penders\u00a0T, Wuensch\u00a0K et al (2017) Underutilization of pharmacotherapy for treatment of alcohol use disorders part II-results from a\u00a0survey of practices among North Carolina mental health providers and brief review of efficacy of available pharmacotherapies. J\u00a0Alcohol Drug Depend 5(5):285","journal-title":"J Alcohol Drug Depend"},{"key":"954_CR98","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40273-015-0272-0","volume":"33","author":"M Stevenson","year":"2015","unstructured":"Stevenson\u00a0M, Pandor\u00a0A, Stevens\u00a0JW et\u00a0al (2015) Nalmefene for reducing alcohol consumption in people with alcohol dependence: an evidence review group perspective of a\u00a0NICE single technology appraisal. PharmacoEconomics 33:833\u2013847","journal-title":"PharmacoEconomics"},{"issue":"4","key":"954_CR99","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2011.03581.x","volume":"107","author":"ST Tiffany","year":"2012","unstructured":"Tiffany\u00a0ST, Friedman\u00a0L, Greenfield\u00a0SF (2012) Beyond drug use: a\u00a0systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction 107(4):709\u2013718","journal-title":"Addiction"},{"key":"954_CR100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W van den Brink","year":"2013","unstructured":"van den Brink\u00a0W, Aubin\u00a0HJ, Bladstr\u00f6m\u00a0A et al (2013) Effiaccy of as-needed nalmefene in alcohol-dependent patients with at least a\u00a0high drinking risk level: results from a\u00a0subgroup analysis of two randomized controlled 6\u2011month studies. Alcohol Alcohol 48:570\u2013578","journal-title":"Alcohol Alcohol"},{"key":"954_CR101","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","volume":"28","author":"W van den Brink","year":"2014","unstructured":"van den Brink\u00a0W, Sorensen\u00a0P, Torup\u00a0L et al (2014) Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a\u00a01-year, randomized controlled study. J\u00a0Psychopharmacol 28:733\u2013744","journal-title":"J Psychopharmacol"},{"key":"954_CR102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","volume":"23","author":"W van den Brink","year":"2018","unstructured":"van den Brink\u00a0W, Addolorato\u00a0G, Aubin\u00a0H\u2011J et al (2018) Efficacy and safety of sodium oxybate in alcohol-dependent patients with a\u00a0very high drinking risk level. Addict Biol 23:969\u2013986","journal-title":"Addict Biol"},{"key":"954_CR103","doi-asserted-by":"crossref","first-page":"107709","DOI":"10.1016\/j.drugalcdep.2019.107709","volume":"206","author":"R Vickers-Smith","year":"2020","unstructured":"Vickers-Smith\u00a0R, Sun\u00a0J, Charnigo\u00a0RJ et al (2020) Gabapentin drug misuse signals: a pharmacovig-ilance assessment using the FDA adverse event reporting system. Drug Alcohol Depend 206:107709","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"954_CR104","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli\u00a0JR, Alterman\u00a0AI, Hayashida\u00a0M et\u00a0al (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49(11):876\u2013880","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"954_CR105","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","volume":"5","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz\u00a0K, Litten\u00a0RZ, Leggio\u00a0L (2019) Advances in the science and treatment of alcohol use disorder. Sci Adv 5(9):eaax4043","journal-title":"Sci Adv"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00954-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-020-00954-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00954-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T23:11:31Z","timestamp":1626822691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-020-00954-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["954"],"URL":"https:\/\/doi.org\/10.1007\/s00115-020-00954-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"21 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Soyka war f\u00fcr Amomed, Camurus, Lundbeck und Indiviorals als Berater t\u00e4tig oder hat Forschungsunterst\u00fctzung oder Referentenhonorare erhalten. S.\u00a0R\u00f6sner gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}